Skip to main content

Advertisement

SpringerLink
Log in

Development and preliminary validation of a risk prediction model for chemotherapy-related nausea and vomiting

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Background

A number of risk factors have been implicated in the development of chemotherapy-induced nausea/vomiting (CINV). Our aim was to develop a risk prediction model and identify patients at high risk for developing CINV before their chemotherapy treatment.

Patients and methods

A multisite, observational, prospective longitudinal design was used. Participants were 336 chemotherapy-naïve cancer patients providing 791 assessments. They completed measures to assess potential risk factors for CINV, including socio-demographic and clinical/treatment-related characteristics, symptom distress, expectations for CINV and state–trait anxiety. CINV was measured with the MASCC Antiemesis Tool. Participants were divided randomly to a training set (=286) and a test set (=50). Random-effects models were run to ascertain the contribution of risk factors in the development of CINV using the training sample. Specificity and sensitivity of the model were assessed in both sets of samples.

Results

Younger age, history of nausea/vomiting, trait anxiety and fatigue were linked with higher levels of CINV, and use of moderately and low emetogenic chemotherapy were linked with lower CINV. The model's specificity were 55.4 and 50.0 % and sensitivity were 80.3 and 79.0 % in the training and test sample, respectively. A dynamic web-based tool is freely available for use by clinicians.

Conclusion

This model of risk prediction for CINV can be an aid to clinical decision-making and assist clinicians to rationalise antiemetic use with their patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Glaus A, Knipping C, Morant R, Bohme C, Lebert B, Beldermann F, Glawogger B, Ortega PF, Husler A, Deuson R (2004) Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer 12:708–715

    Article  PubMed  Google Scholar 

  2. Molassiotis A, Saunders MP, Valle J, Wilson G, Lorigan P, Wardley A, Levine E, Cowan R, Loncaster J, Rittenberg C (2008) A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer 16(2):201–208

    Article  CAS  PubMed  Google Scholar 

  3. Molassiotis A, Farrell C, Bourne K, Brearley SG, Pilling M (2012) An exploratory study to clarify the cluster of symptoms predictive of chemotherapy-induced nausea using random forest modelling. J Pain Symptom Manage 44(5):692–703

    Article  PubMed  Google Scholar 

  4. Sun CC, Bodurka DC, Weaver CB et al (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13:219–227

    Article  PubMed  Google Scholar 

  5. Osoba D, Zee B, Warr D et al (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. Support Care Cancer 5:307–313

    Article  CAS  PubMed  Google Scholar 

  6. Rusthoven JJ, Osoba D, Butts CA et al (1998) The impact of postchemotherapy nausea and vomiting on quality of life after moderately emetogenic chemotherapy. Support Care Cancer 6:389–395

    Article  CAS  PubMed  Google Scholar 

  7. Farrell C, Brearley SG, Pilling M, Molassiotis A. The impact of chemotherapy-induced nausea on patients' nutritional status, psychological distress and quality of life. (accepted for publication, subject to minor corrections).

  8. Molassiotis A, Stricker CT, Eaby B, Velders L, Coventry PA (2008) Understanding the concept of chemotherapy-related nausea: the patient experience. Eur J Cancer Care 17:444–453

    Article  CAS  Google Scholar 

  9. Molassiotis A, Brearley SG, Stamataki Z (2011) Use of antiemetics in the management of chemotherapy-related nausea and vomiting in current UK practice. Support Care Cancer 19(7):949–956

    Article  PubMed  Google Scholar 

  10. Aapro M, Molassiotis A, Dicato M, Peláez I, Rodríguez-Lescure A, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F; on behalf of the PEER investigators. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 2012. [Epub ahead of print].

  11. Molassiotis A, Yam BM, Yung H, Chan FY, Mok TS (2002) Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients. Support Care Cancer 10(2):139–145

    Article  CAS  PubMed  Google Scholar 

  12. Pirri C, Katris P, Trotter J, Bayliss E, Bennett R, Drummond P (2011) Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study. Support Care Cancer 19(10):1549–1563

    Article  PubMed  Google Scholar 

  13. Warr DG, Street JC, Carides AD (2011) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Support Care Cancer 19(6):807–813

    Article  PubMed  Google Scholar 

  14. Dranitsaris G, Joy A, Young S, Clemons M, Callaghan W, Petrella T (2009) Identifying patients at high risk for nausea and vomiting after chemotherapy: the development of a practical prediction tool. I. Acute nausea and vomiting. J Support Oncol 7:W1–W8

    Google Scholar 

  15. Petrella T, Clemons M, Joy A, Young S, Callaghan W, Dranitsaris G (2009) Identifying patients at high risk for nausea and vomiting after chemotherapy: the development of a practical validated prediction tool. II. Delayed nausea and vomiting. J Support Oncol 7:W9–W16

    Google Scholar 

  16. Nunnally JC (1978) Psychometric theory. McGraw-Hill, New York

    Google Scholar 

  17. Roila F, Hesketh PJ, Herrstedt J (2006) Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17:20–28

    Article  CAS  PubMed  Google Scholar 

  18. Roscoe JA, Bushunow P, Morrow GR et al (2004) Patient expectation is a strong predictor of severe nausea after chemotherapy: a University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma. Cancer 101:2701–2708

    Article  PubMed  Google Scholar 

  19. Montgomery GH, Bovbjerg DH (2000) Pre-infusion expectations predict post-treatment nausea during repeated adjuvant chemotherapy infusions for breast cancer. Br J Health Psychol 5:105–119

    Article  Google Scholar 

  20. Spielberger CD, Lushene RE. State trait anxiety inventory test manual. P.A.C.P Press. 1983.

  21. McCorkle R, Young K (1978) The development of a symptom distress scale. Cancer Nurs 1(5):373–378

    Article  CAS  PubMed  Google Scholar 

  22. Molassiotis A, Coventry PA, Stricker CT, Clements C, Eaby B, Velders L, Rittenberg C, Gralla RJ (2007) Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemesis tool. J Pain Symptom Manage 34(2):148–159

    Article  PubMed  Google Scholar 

  23. Royston P (2005) Multiple imputation of missing values: Update of ice. Stata J 5(4):527–536

    Google Scholar 

  24. Chatterjee S, Hadi AS (2006) Regression analysis by example, 4th edn. Wiley, Hoboken

    Book  Google Scholar 

  25. Hesketh PJ, Aapro M, Street JC, Carides AD (2010) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer 18(9):1171–1177

    Article  PubMed  Google Scholar 

  26. Shih V, Wan HS, Chan A (2009) Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide. Ann Pharmacother 43(3):444–452

    Article  PubMed  Google Scholar 

  27. Koffman J, Higginson IJ, Donaldson N (2003) Symptom severity in advanced cancer, assessed in two ethnic groups by interviews with bereaved family members and friends. J R Soc Med 96(1):10–6

    Article  PubMed  Google Scholar 

  28. Xu L, Koch KL, Summy-Long J, Stern RM, Seaton JF (1993) Hypothalamic and gastric myoelectrical responses during vection-induced nausea in healthy Chinese subjects. Am J Physiol 265:E578–584

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was funded by an unrestricted grant from Merck & Co., Ltd.

Conflict of interest

AM has received honoraria from Merck & Co, Roche UK, ProStrakan, and Bayer; received grants from Merck & Co; Roche UK and Acacia Pharma, and is an international advisory board member for Merck & Co. All remaining authors have declared no conflict of interest.

Author information

Authors and Affiliations

  1. School of Nursing, Midwifery & Social Work, University of Manchester, Manchester, UK

    A. Molassiotis & Z. Stamataki

  2. School of Nursing, Hong Kong Polytechnic University, Hong Kong, China

    A. Molassiotis

  3. Christie NHS Foundation Trust, Manchester, UK

    Z. Stamataki

  4. Centre for Primary Care, Institute of Population Health, University of Manchester, Manchester, UK

    E. Kontopantelis

  5. Centre for Biostatistics, Institute of Population Health, University of Manchester, Manchester, UK

    E. Kontopantelis

Authors
  1. A. Molassiotis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Z. Stamataki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Kontopantelis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Molassiotis.

Additional information

Registration

This study was registered with the UKCRN Portfolio database, ID number 7587.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Molassiotis, A., Stamataki, Z. & Kontopantelis, E. Development and preliminary validation of a risk prediction model for chemotherapy-related nausea and vomiting. Support Care Cancer 21, 2759–2767 (2013). https://doi.org/10.1007/s00520-013-1843-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-013-1843-2

Keywords

Search

Navigation